Expertise in
8
conditions
Expertise in
8
conditions
Osf Saint Francis-Radiation Oncology
530 NE Glen Oak Ave, 
Peoria, IL 

Overview

Pedro De Alarcon is a Hematologist and an Oncologist in Peoria, Illinois. Dr. De Alarcon is highly rated in 8 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hepatoblastoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 49 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Osf Saint Francis-Radiation Oncology
530 NE Glen Oak Ave, Peoria, IL 61637

Additional Areas of Focus

Dr. De Alarcon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


49 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Umbrella Long-Term Follow-Up Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 44 Less Clinical Trials
Similar Doctors
Expertise in
8
conditions
Hematology | Oncology
Expertise in
8
conditions
Hematology | Oncology

Bleeding And Clotting Disorders Institute

427 W Northmoor Rd, 
Peoria, IL 
 (4.2 miles away)
Languages Spoken:
English
Offers Telehealth

Jonathan Roberts is a Hematologist and an Oncologist in Peoria, Illinois. Dr. Roberts is highly rated in 8 conditions, according to our data. His top areas of expertise are Blood Clots, Von Willebrand Disease (VWD), Hemophilia A, and Hemophilia B.

Expertise in
19
conditions
Expertise in
19
conditions

Bleeding And Clotting Disorders Institute

427 W Northmoor Rd, 
Peoria, IL 
 (4.2 miles away)
Languages Spoken:
English

Michael Tarantino is a Hematologist in Peoria, Illinois. Dr. Tarantino is highly rated in 19 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Thrombocytopenia, Hemophilia A, and Splenectomy.

Expertise in
17
conditions
Hematology | Oncology
Expertise in
17
conditions
Hematology | Oncology

Office

900 N 1st St, 
Springfield, IL 
 (61.6 miles away)
Languages Spoken:
English

Preetpaul Singh is a Hematologist and an Oncologist in Springfield, Illinois. Dr. Singh is highly rated in 17 conditions, according to our data. His top areas of expertise are Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Colonoscopy.

Frequently Asked Questions about Dr. Pedro De Alarcon

How do I make an appointment with Dr. Pedro De Alarcon?

You can book an appointment with Dr. Pedro De Alarcon by calling their office at 309-655-4242. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pedro De Alarcon a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pedro De Alarcon is classified as an Distinguished expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pedro De Alarcon specialize in?

While Dr. Pedro De Alarcon is a Hematology, they have specific expertise in Hodgkin Lymphoma, Neuroblastoma, and Embryonal Tumor with Multilayered Rosettes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Pedro De Alarcon participate in research or clinical trials?

Yes. Dr. Pedro De Alarcon has published 35 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Pedro De Alarcon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pedro De Alarcon accept my insurance?

Dr. Pedro De Alarcon accepts most major insurance plans, including Humana. We recommend calling the office directly at 309-655-4242 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. De Alarcon's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile